GSK's Pandemrix problems rumble on
This article was originally published in Scrip
Executive Summary
UK media reports suggesting that the British government is preparing to pay out £1m each to an alleged 60 patients who developed narcolepsy following administration of Pandemrix, have once again turned the spotlight onto the rare adverse event. GlaxoSmithKline – which produced Pandemrix – declined to comment on the latest reports but appears to have shifted slightly from its position a year ago that data were "insufficient" to assess the likelihood of a causal association between Pandemrix and narcolepsy (scripintelligence.com, 27 February 2013).